General literature
Defining and using immune archetypes to classify and treat cancer

Combes A. J., Samad B., Krummel M. F.

Nat Rev Cancer. 2023, 23(7):491-505.

DOI
PubMed
General literature
Discovering dominant tumor immune archetypes in a pan-cancer census

Combes A. J., Samad B., Tsui J., Chew N. W., Yan P., Reeder G. C., Kushnoor D., Shen A., Davidson B., Barczak A. J., Adkisson M., Edwards A., Naser M., Barry K. C., Courau T., Hammoudi T., Argüello R. J., Rao A. A., Olshen A. B., Cai C., Zhan J., Davis K. C., Kelley R. K., Chapman J. S., Atreya C. E., Patel A., Daud A. I., Ha P., Diaz A. A., Kratz J. R., Collisson E. A., Fragiadakis G. K., Erle D. J., Boissonnas A., Asthana S., Chan V., Krummel M. F.

Cell. 2022, 185(1):184-203.e19.

DOI
PubMed
General literature
Archetypes of checkpoint-responsive immunity

Im K., Combes A. J., Spitzer M. H., Satpathy A. T., Krummel M. F.

Trends Immunol. 2021, 42(11):960-974.

DOI
PubMed
General literature
Immunity as a continuum of archetypes

Mujal A. M., Krummel M. F.

Science. 2019, 364(6435):28-29.

DOI
PubMed
Success examples
Recent advances in the development of 17beta-hydroxysteroid dehydrogenase inhibitors

Poirier D.

Steroids. 2025, 213:109529.

DOI
PubMed
Success examples
Targeting of MMP-13 prevents aortic aneurysm formation in Marfan mice

Zimmermann LM. A., Furlan A.G., Mehrkens D., Geißen S., Zuk A.V., Pryymachuk G., Pykarek N., van Beers T., Sonntag-Bensch D., Marzi J., Schenke-Layland K., Brinckmann J., Zigrino P., Grandoch M., Baldus S., Sengle G.

bioRxiv 2022, 518511.

MMP-13 antagonist
DOI